Pharmaceutical Technology

APRIL 4, 2023

Formerly known as CTX001, exa-cel is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy. Vertex Pharmaceuticals chief medical officer and Global Medicines Development and Medical Affairs executive vice-president Carmen Bozic said: “The completion of our exa-cel global regulatory filings is a historic milestone.

Gene Therapy 246

Gene Therapy Gene Editing In-Vivo Gene 246

The Pharma Data

NOVEMBER 17, 2020

Francisco “Paco” Arredondo, MD, MPH, FACOG, recently Chief Medical Officer of the United States largest network of fertility centers, overseeing more than 50 fertility specialists, and currently a partner in a joint venture developing INVOcell clinics in Mexico. . SARASOTA, Fla. ,

In-Vivo 52

In-Vivo In-Vitro Genetics Doctors 52

XTalks

FEBRUARY 10, 2023

These details must be thoughtfully considered early in clinical development to ensure studies are completed within the projected timeline and budget,” added Dr. “These details must be thoughtfully considered early in clinical development to ensure studies are completed within the projected timeline and budget,” added Dr. Vassallo.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Gene Therapy 52